We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NeuroSolutions Enters into a Collaboration Agreement with Gentronix
News

NeuroSolutions Enters into a Collaboration Agreement with Gentronix

NeuroSolutions Enters into a Collaboration Agreement with Gentronix
News

NeuroSolutions Enters into a Collaboration Agreement with Gentronix

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NeuroSolutions Enters into a Collaboration Agreement with Gentronix "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NeuroDiscovery Ltd has announced that its 100% subsidiary, NeuroSolutions Ltd has entered into a collaborative agreement with Gentronix Ltd to accelerate the pre-clinical development of NSL-105.

Pursuant to the agreement both companies will seek to assess the genetic toxicology of NSL-105 by using GreenScreen, Gentronix’s commercially available yeast-based assay.

In particular, the assay’s specificity is demonstrated by the extremely low incidence of false positives compared to other available tests.

NeuroDiscovery Chairman, Dr Mark Treherne said, "We are delighted to collaborate with Gentronix and this agreement will provide us with a significant opportunity to accelerate the development of NSL-105 to build an in-depth pipeline of innovative products for the treatment of a variety of painful medical conditions."

"Recent forecasts predict a global market value for neuropathic pain treatments of over US$4 billion by 2007."

Advertisement